Ajooni Biotech Limited has submitted the Exchange a copy Scrutinizers' report along with voting results of 15th Annual General Meeting held on September 29, 2025
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech Limited held its 15th AGM on September 29, 2025 via video conferencing, where all 14 resolutions were passed with the requisite majority. Approval rates ranged from 97.62% to 99.99% across resolutions. Key items included adoption of FY2024-25 audited financial statements, re-appointment of Mr. Partek Singh (rotational director), Mr. Gursimran Singh (Whole-Time Director) and Mr. Jasjot Singh (Managing Director with increased remuneration). Five related party transactions were approved with Healthy Biosciences, Punjab Biotechnology Park, Gilbert Kasauli, Revive Aesthetics and Khanna Solvex. M/s. SDK & Associates was appointed as Secretarial Auditor for a five-year term (FY2025-26 to FY2029-30), and authorities under Sections 185 and 186 of the Companies Act for loans and investments were also approved. Out of 63,791 total shareholders on record date, only 55 public shareholders and 6 promoter representatives attended via VC, with public non-institutional voting participation at roughly 2.97% of their shareholding on most items.
All resolutions passed with overwhelming support, signalling smooth board continuity and management endorsement. Retail investors should note the low public voting turnout and the approval of related party transactions and a higher remuneration for the Managing Director, which are worth tracking for governance and related-party risk.